Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer drug ART6043 enters human trials for advanced tumors

NCT ID NCT05898399

Recruiting now Disease control Sponsor: Artios Pharma Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the main focus is on finding the right dose and seeing if it is safe enough to study further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ART6043 (a DNA polymerase theta inhibitor) and olaparib
What this could lead to
If successful, this could provide a new treatment option for people with advanced or metastatic solid tumors, potentially slowing disease progression.
What could go wrong
This is an early-phase trial (Phase 1/2a) with a small number of participants, so the drug may not prove effective or safe. Side effects are possible, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Her2-receptor negative breast cancer metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Hospital Clínico Universitario de Valladolid

    RECRUITING

    Valladolid, Castille and León, 47003, Spain

  • Hospital San Pedro de Alcántara

    RECRUITING

    Cáceres, Extremadura, 10003, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, Madrid, 28041, Spain

  • Hospital Universitario Clínico San Cecilio

    RECRUITING

    Granada, Andalusia, 18007, Spain

  • Hospital de la Santa Creu i Sant Pau

    RECRUITING

    Barcelona, Catalonia, 08025, Spain

  • Jefferson University Hospitals - Kimmel Cancer Center

    ACTIVE_NOT_RECRUITING

    Philadelphia, Pennsylvania, 17107, United States

  • Mary Crowley Cancer Center - Clinic

    COMPLETED

    Dallas, Texas, 75251, United States

  • Memorial Sloan-Kettering Cancer Center (MSKCC)

    ACTIVE_NOT_RECRUITING

    New York, New York, 10065-6800, United States

  • SCRI oncology partners

    COMPLETED

    Nashville, Tennessee, 37203, United States

  • South Texas Accelerated Research Therapeutics (START) - Midwest

    ACTIVE_NOT_RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • Stephenson Cancer Center - Oncology

    ACTIVE_NOT_RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

  • The University of Texas - MD Anderson Cancer Center

    ACTIVE_NOT_RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.